Deriving income from letting somebody else pursue a direction you weren't prioritizing is always a good business strategy, which is what Tesaro Inc. did by out-licensing niraparib in prostate cancer to Janssen Biotech Inc. while retaining all other rights to the poly ADP-ribose polymerase (PARP) inhibitor.
Competition among PARP inhibitor developers was heightened when AstraZeneca PLC obtained limited US FDA approval for Lynparza (olaparib) in third-line ovarian cancer in late 2014. Tesaro plans to continue focusing...